Literature DB >> 15811941

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Scott Q Harper1, Patrick D Staber, Xiaohua He, Steven L Eliason, Inês H Martins, Qinwen Mao, Linda Yang, Robert M Kotin, Henry L Paulson, Beverly L Davidson.   

Abstract

Huntington's disease (HD) is a fatal, dominant neurogenetic disorder. HD results from polyglutamine repeat expansion (CAG codon, Q) in exon 1 of HD, conferring a toxic gain of function on the protein huntingtin (htt). Currently, no preventative treatment exists for HD. RNA interference (RNAi) has emerged as a potential therapeutic tool for treating dominant diseases by directly reducing disease gene expression. Here, we show that RNAi directed against mutant human htt reduced htt mRNA and protein expression in cell culture and in HD mouse brain. Importantly, htt gene silencing improved behavioral and neuropathological abnormalities associated with HD. Our data provide support for the further development of RNAi for HD therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811941      PMCID: PMC556303          DOI: 10.1073/pnas.0501507102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Huntington's disease in children. Neuropathologic study of four cases.

Authors:  R K Byers; F H Gilles; C Fung
Journal:  Neurology       Date:  1973-06       Impact factor: 9.910

2.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

3.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

4.  Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.

Authors:  J K White; W Auerbach; M P Duyao; J P Vonsattel; J F Gusella; A L Joyner; M E MacDonald
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

5.  Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat.

Authors:  Christine M Ambrose; Mabel P Duyao; Glenn Barnes; Gillian P Bates; Carol S Lin; Jayalakshmi Srinidhi; Sarah Baxendale; Holger Hummerich; Hans Lehrach; Michael Altherr; John Wasmuth; Alan Buckler; Deanna Church; David Housman; Mary Berks; Gos Micklem; Richard Durbin; Alan Dodge; Andrew Read; James Gusella; Marcy E MacDonald
Journal:  Somat Cell Mol Genet       Date:  1994-01

Review 6.  Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect.

Authors:  Michael S Levine; Carlos Cepeda; Miriam A Hickey; Sheila M Fleming; Marie-Françoise Chesselet
Journal:  Trends Neurosci       Date:  2004-11       Impact factor: 13.837

7.  Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.

Authors:  P H Reddy; M Williams; V Charles; L Garrett; L Pike-Buchanan; W O Whetsell; G Miller; D A Tagle
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

8.  Inactivation of the mouse Huntington's disease gene homolog Hdh.

Authors:  M P Duyao; A B Auerbach; A Ryan; F Persichetti; G T Barnes; S M McNeil; P Ge; J P Vonsattel; J F Gusella; A L Joyner
Journal:  Science       Date:  1995-07-21       Impact factor: 47.728

9.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.

Authors:  G Schilling; M W Becher; A H Sharp; H A Jinnah; K Duan; J A Kotzuk; H H Slunt; T Ratovitski; J K Cooper; N A Jenkins; N G Copeland; D L Price; C A Ross; D R Borchelt
Journal:  Hum Mol Genet       Date:  1999-03       Impact factor: 6.150

10.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

Authors:  J Nasir; S B Floresco; J R O'Kusky; V M Diewert; J M Richman; J Zeisler; A Borowski; J D Marth; A G Phillips; M R Hayden
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

View more
  271 in total

1.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

Review 2.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

3.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies.

Authors:  Ying Poi Liu; Monique A Vink; Jan-Tinus Westerink; Eva Ramirez de Arellano; Pavlina Konstantinova; Olivier Ter Brake; Ben Berkhout
Journal:  RNA       Date:  2010-05-24       Impact factor: 4.942

4.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 5.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 6.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

7.  "Huntingtin holiday": progress toward an antisense therapy for Huntington's disease.

Authors:  Xiao-Hong Lu; X William Yang
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

8.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

9.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

10.  Moving toward a gene therapy for Huntington's disease.

Authors:  J C Glorioso; J B Cohen; D L Carlisle; I Munoz-Sanjuan; R M Friedlander
Journal:  Gene Ther       Date:  2015-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.